A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis



Status:Archived
Conditions:Arthritis, Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery, Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:December 2009
End Date:July 2013

Use our guide to learn which trials are right for you!

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis


The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms)
and safety of ustekinumab in patients with psoriatic arthritis.


This study is a randomized (patients are assigned different treatments based on chance),
double-blind (neither the patient nor the physician knows whether drug or placebo is being
taken, or at what dosage), parallel-group, multicenter study to evaluate the effectiveness
and safety of ustekinumab compared to placebo in the treatment of patients with active
psoriatic arthritis. The primary effectiveness endpoint will be measured by the reduction in
signs and symptoms of arthritis, as defined by 20% improvement from baseline in American
College of Rheumatology (ACR) measurements of arthritis at Week 24. The study will
additionally look at higher levels of joint improvement (ie, 50% or 70% improvement from
baseline) and improvement in activity and quality of life, as well as the impact of
ustekinumab on psoriatic skin lesions. Safety assessments will be performed throughout the
study and include obtaining and evaluating laboratory tests, vital signs (eg, blood
pressure) and the occurrence and severity of adverse events (side effects). Patients will be
assigned to one of three treatment groups. Patients will receive either 45 mg ustekinumab,
90 mg ustekinumab or placebo at Weeks 0, 4, and every 12 weeks until Week 88. Patients who
do not have >=5% improvement in their disease (tender and swollen joints) at Week 16 may be
eligible to receive an increase or change to their ustekinumab dosage. Ustekinumab 45 mg, 90
mg, or placebo subcutaneous injections at Weeks 0 and 4 followed by every-12-week dosing
with the last dose at Week 88. Early escape possibility at Week 16. Patients randomized to
placebo will crossover to receive ustekinumab at Weeks 24 and 28 followed by every-12-week
dosing with the last dose at Week 88. Expected duration of exposure to study agent is 100
weeks.


We found this trial at
21
sites
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts
?
mi
from
Boston, MA
Click here to add this to my saved trials
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Centralia, Illinois
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Jeffersonville, Indiana
?
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
?
mi
from
Lima, OH
Click here to add this to my saved trials
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Metairie, Louisiana
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Nashville, Tennessee
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Omaha, Nebraska
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ponca City, Oklahoma
?
mi
from
Ponca City, OK
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
St Louis, Missouri
?
mi
from
St Louis, MO
Click here to add this to my saved trials
West Orange, New Jersey
?
mi
from
West Orange, NJ
Click here to add this to my saved trials